AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

CDNA · NASDAQ · Medical - Diagnostics & Research

CareDx (CDNA)

Runs transplant testing, patient tools, and workflow support around organ health.

$57.26

After hours+0.77 (+1.36%)

At close$56.49(+3.98%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	67	66	72	92	83	87	85	87	100	108	118	132
Cost of revenue	25	26	26	28	28	28	28	29	31	36	34	35
Gross profit	43	40	46	64	55	58	56	58	69	73	84	97
	71	163	65	72	66	−16	64	69	70	79	82	97
Research & development	19	18	19	20	17	17	19	17	17	19	21	22
	52	47	47	52	48	62	46	52	53	60	61	74
Selling & marketing	18	20	20	21	20	21	23	24	24	31	30	33
General & administrative	34	27	27	31	29	41	23	28	28	29	30	41
Other expenses	0	98	0	0	0	−95	0	0	0	0	0	0
Operating income	−29	−123	−19	−7	−10	75	−8	−11	0	−6	2	0
	5	5	3	3	3	3	−2	2	2	2	1	114
Interest income	3	3	3	3	3	3	3	2	2	2	2	2
Other non-operating income	0	−98	−3	−3	−3	95	0	0	0	0	0	0
Income before tax	−24	−118	−17	−5	−7	78	−10	−9	2	−4	3	115
Income tax expense	0	0	0	0	0	0	0	0	0	0	0	4
Net income from continuing operations	−23	−118	−17	−5	−7	78	−10	−9	2	−4	3	111
Net income	−23	−118	−17	−5	−7	78	−10	−9	2	−4	3	111
EPS, basic	−$0.43	−$2.24	−$0.38	−$0.09	−$0.14	$1.62	−$0.19	−$0.16	$0.03	−$0.08	$0.05	$2.15
EPS, diluted	−$0.43	−$2.24	−$0.38	−$0.09	−$0.14	$1.51	−$0.19	−$0.16	$0.03	−$0.08	$0.05	$2.07
Weighted average shares, basic	54	53	52	52	53	54	55	54	53	51	51	51
Weighted average shares, diluted	54	53	52	52	53	58	55	54	54	51	53	53
EBITDA	−24	−20	−12	0	−2	−15	−3	−6	5	−1	7	4
Depreciation & amortization	5	5	5	5	5	5	5	5	5	5	5	4
EBIT	−29	−25	−17	−5	−7	−20	−8	−11	0	−6	2	0